Motives for reporting adverse drug reactions by patient-reporters in the Netherlands

por van Hunsel, Florence, van der Welle, Christine, Passier, Anneke, van Puijenbroek, Eugène, van Grootheest, Kees
Publicado 2010

‘Care for Outcomes’: systematic development of a set of outcome indicators to improve patient-relevant outcomes for patients with lung cancer

por Cramer-van der Welle, Christine M, van Loenhout, Lotte, van den Borne, Ben EEM, Schramel, Franz MNH, Dijksman, Lea M
Publicado 2021

Real‐world treatment patterns and outcomes of patients with extensive disease small cell lung cancer

por Cramer‐van der Welle, Christine M., Schramel, Franz M. N. H., van Leeuwen, Arvid S., Groen, Harry J. M., van de Garde, Ewoudt M. W.
Publicado 2020

Trends in Drug Costs and Overall Survival in Patients with Metastatic Non-small Cell Lung Cancer in The Netherlands Diagnosed from 2008 Through 2014

por Cramer-van der Welle, Christine M., Peters, Bas J. M., Deenen, Maarten J., Schramel, Franz M. N. H., van de Garde, Ewoudt M. W.
Publicado 2020

Systematic evaluation of the efficacy–effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer

por Cramer-van der Welle, Christine M., Peters, Bas J.M., Schramel, Franz M.N.H., Klungel, Olaf H., Groen, Harry J.M., van de Garde, Ewoudt M.W.
Publicado 2018

Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands

por Cramer-van der Welle, Christine M., Verschueren, Marjon V., Tonn, Merel, Peters, Bas J. M., Schramel, Franz M. N. H., Klungel, Olaf H., Groen, Harry J. M., van de Garde, Ewoudt M. W.
Publicado 2021